EUVIMEDEUVIMED entdecken
Crossref

Differences in SARS-CoV-2 rapid diagnostic testing usage by COVID-19 vaccination status can bias vaccine effectiveness estimates against symptomatic SARS-CoV-2 infection from a test-negative design

Ryan E Wiegand iD, Gordana Derado iD, Allison Avrich Ciesla, Saba A Qasmieh iD, Jill M Ferdinands, Brendan Flannery, Ruth Link-Gelles iD

International Journal of Epidemiology · 14.10.2026 · 55 (6)

DOI: 10.1093/ije/dyag226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Epidemiology, online erschienen am 23.10.2026. Verfasst von Ryan E Wiegand und 6 weiteren Autor:innen. Beteiligte Einrichtung: Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA, United States. Hauptthemen laut MEDLINE: COVID-19, Vaccine Efficacy, Rapid Diagnostic Tests, COVID-19 Vaccines. Die Arbeit nennt 51 Literaturangaben. Gefördert von: US Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Use of rapid diagnostic tests (RDTs) may bias vaccine effectiveness (VE) estimates from test-negative design (TND) studies. We conducted individual-level simulations using national, US COVID-19 surveillance data to assess potential bias at varying likelihoods of visiting a healthcare facility and prevalence of RDT use.

Methods

Twenty-one scenarios that varied the probabilities of visiting a healthcare facility and RDT use by vaccination status were simulated. VE was calculated as 100 × (1 − odds ratio), comparing the odds of symptomatic SARS-CoV-2 infection between vaccinated and unvaccinated groups of people. VE estimates were compared to VE estimates from simulations without RDT testing to calculate the bias in percentage points (pp).

Results

VE was underestimated when either vaccinated people were more likely (probability of .5) than unvaccinated people (probability of .3) to visit a healthcare facility after a positive RDT [−5.8%age points (pp); 95% uncertainty interval (UI): −9.1, −2.4] or unvaccinated people were more likely than vaccinated people to visit a healthcare facility after a negative RDT (bias = −6.1 pp; UI: −9.9, −2.5). Conversely, VE was overestimated when either vaccinated people were more likely than unvaccinated people to visit a healthcare facility after a negative RDT (bias = 5.2; UI: 2.4, 7.7) or unvaccinated people were more likely than vaccinated people to visit a healthcare facility after a positive RDT (bias = 8.4 pp; UI: 5.6, 11.3).

Conclusion

VE estimates against symptomatic SARS-CoV-2 infection from a TND may be under- or overestimated, depending on differences in RDT usage between vaccination groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Vaccine EfficacyRapid Diagnostic TestsCOVID-19 VaccinesVaccinationCoronavirus InfectionsHumansSARS-CoV-2FemaleBiasUnvaccinated PersonsAdultMaleMiddle AgedUnited StatesCOVID-19 TestingPandemicsAdolescentBetacoronavirusAgedYoung Adult

Stichwörter der Autor:innen

rapid diagnostic testtest-negative designvaccine effectiveness

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Eagle Health Analytics, San Antonio, TX, United States.
  • Institute for Implementation Science in Population Health, City University of New York, New York, NY, United States.
  • Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York, New York, NY, United States.
  • Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • US Public Health Service Commissioned Corps, Rockville, MD, United States.

ORCID-Profile: Ryan E Wiegand, Gordana Derado, Saba A Qasmieh, Ruth Link-Gelles

Förderung

  • US Centers for Disease Control and Prevention

Zitieren

APA

Wiegand, R. E., Derado, G., Ciesla, A. A., Qasmieh, S. A., Ferdinands, J. M., Flannery, B., & Link-Gelles, R. (2026). Differences in SARS-CoV-2 rapid diagnostic testing usage by COVID-19 vaccination status can bias vaccine effectiveness estimates against symptomatic SARS-CoV-2 infection from a test-negative design. International Journal of Epidemiology, 55(6). https://doi.org/10.1093/ije/dyag226

Vancouver

Wiegand RE, Derado G, Ciesla AA, Qasmieh SA, Ferdinands JM, Flannery B, et al. Differences in SARS-CoV-2 rapid diagnostic testing usage by COVID-19 vaccination status can bias vaccine effectiveness estimates against symptomatic SARS-CoV-2 infection from a test-negative design. International Journal of Epidemiology. 2026;55(6). doi:10.1093/ije/dyag226

BibTeX
@article{Wiegand2026,
  author = {Wiegand, Ryan E and Derado, Gordana and Ciesla, Allison Avrich and Qasmieh, Saba A and Ferdinands, Jill M and Flannery, Brendan and Link-Gelles, Ruth},
  title = {Differences in SARS-CoV-2 rapid diagnostic testing usage by COVID-19 vaccination status can bias vaccine effectiveness estimates against symptomatic SARS-CoV-2 infection from a test-negative design},
  journal = {International Journal of Epidemiology},
  year = {2026},
  volume = {55},
  number = {6},
  doi = {10.1093/ije/dyag226}
}
Kostenlos starten →